HER2-POSITIVE EARLY BREAST CANCER
Clinical trials for HER2-POSITIVE EARLY BREAST CANCER explained in plain language.
Never miss a new study
Get alerted when new HER2-POSITIVE EARLY BREAST CANCER trials appear
Sign up with your email to follow new studies for HER2-POSITIVE EARLY BREAST CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo aims to wipe out aggressive breast cancer before surgery
Disease control OngoingThis phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a Chemo-Free cocktail beat early breast cancer?
Disease control OngoingThis phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2 • Sponsor: MedSIR • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
New pill combo aims to wipe out breast tumors before surgery
Disease control OngoingThis study tests whether adding the targeted drug pyrotinib to standard chemotherapy and trastuzumab can completely eliminate HER2-positive breast tumors before surgery. About 113 women with early-stage HER2+ breast cancer will receive the combination, then have surgery to check …
Matched conditions: HER2-POSITIVE EARLY BREAST CANCER
Phase: PHASE2, PHASE3 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC